Arbutus Biopharma Corp (ABUS)
3.735
+0.08
(+2.33%)
USD |
NASDAQ |
Nov 14, 12:29
Arbutus Biopharma Cash from Investing (Quarterly): -11.99M for Sept. 30, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -11.99M |
| June 30, 2024 | 9.829M |
| March 31, 2024 | 11.69M |
| December 31, 2023 | 22.22M |
| September 30, 2023 | 10.43M |
| June 30, 2023 | 1.441M |
| March 31, 2023 | 16.68M |
| December 31, 2022 | 12.68M |
| September 30, 2022 | -13.74M |
| June 30, 2022 | -13.83M |
| March 31, 2022 | -60.06M |
| December 31, 2021 | -8.121M |
| September 30, 2021 | 15.97M |
| June 30, 2021 | -38.75M |
| March 31, 2021 | 18.22M |
| December 31, 2020 | -49.98M |
| September 30, 2020 | 14.10M |
| June 30, 2020 | 23.37M |
| March 31, 2020 | -2.401M |
| December 31, 2019 | -58.82M |
| September 30, 2019 | 16.16M |
| June 30, 2019 | 9.972M |
| March 31, 2019 | 61.03M |
| December 31, 2018 | 44.78M |
| September 30, 2018 | 11.78M |
| Date | Value |
|---|---|
| June 30, 2018 | 14.98M |
| March 31, 2018 | -75.67M |
| December 31, 2017 | 0.709M |
| September 30, 2017 | 5.306M |
| June 30, 2017 | -1.385M |
| March 31, 2017 | 23.20M |
| December 31, 2016 | 0.731M |
| September 30, 2016 | -0.879M |
| June 30, 2016 | -85.39M |
| March 31, 2016 | -13.58M |
| December 31, 2015 | -1.804M |
| September 30, 2015 | -17.73M |
| June 30, 2015 | -10.33M |
| March 31, 2015 | 37.55M |
| December 31, 2014 | 1.058M |
| September 30, 2014 | -0.443M |
| June 30, 2014 | -43.24M |
| March 31, 2014 | -0.335M |
| December 31, 2013 | -0.194M |
| September 30, 2013 | -0.12M |
| June 30, 2013 | -0.21M |
| March 31, 2013 | -0.201M |
| December 31, 2012 | -0.0016M |
| September 30, 2012 | 0.0021M |
| June 30, 2012 | -0.0117M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-60.06M
Minimum
Mar 2022
23.37M
Maximum
Jun 2020
-5.052M
Average
5.635M
Median
Cash from Investing (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | -16.16M |
| Amicus Therapeutics Inc | 34.27M |
| Ionis Pharmaceuticals Inc | -340.80M |
| GlycoMimetics Inc | -0.0025M |
| FibroGen Inc | 72.24M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -20.74M |
| Cash from Financing (Quarterly) | 1.775M |
| Free Cash Flow | -71.92M |
| Free Cash Flow Per Share (Quarterly) | -0.1097 |
| Free Cash Flow to Equity (Quarterly) | -20.74M |
| Free Cash Flow Yield | -10.68% |